My-La CD8+

95051033, human lymph, Lymphoblastoid

• Code UNSPSC : 41106514

Propriétés

• product name: My-La CD8+, 95051033
• Source biologique: human lymph
• Mode de croissance: Suspension
• Caryotype: Not specified
• Morphologie: Lymphoblastoid
• Produits: Not specified
• Récepteurs: Not specified
• Technique(s): cell culture | mammalian: suitable
• Maladie(s) pertinente(s): cancer
• Conditions d'expédition: dry ice
• Température de stockage: −196°C

Description

Origine de la lignée cellulaire

Human Caucasian T Lymphocyte, mycosis fungoides.

Description de la lignée cellulaire

The cell line My-La, CD8+, also known as My-La, marker chromosome was established from a plaque biopsy of an 82 year old Caucasian patient with mycosis fungoides stage II. Together with My-La, CD8+ a second cell line has been established (My-La, CD4+ Sigma Catalogue number. 95051032) by including IL-2 and IL-4 in the culture medium. My-La, CD8+ shows characteristic chromosome markers, express ß-13 of the T-cell receptor and are double homozygous for HLA-A1.B8. Phenotypically a weak staining was observed for CD2, CD3, CD8, CD25, CD71 and TCR-1 α / ß. There has been no evidence of HTLV-I infection in the cell line and serum from the patient did not demonstrate antibodies against HTLV-I and HTLV-II. My-La, CD8+ cells show a low viability after resuscitation from frozen and a long lag time phase until exponential growth is reached.

Application

Study of antigen-independent proliferation of T- cell lyphoma from mycosis fungoides patient.

Milieu de culture

RPMI 1640 + 2mM Glutamine + 100 u/ml IL-2 + 10% human AB seum

Procédure de repiquage

Maintain cultures between 3-9 x 100,000 cells/ml; 5% CO₂; 37°C. Split only 1:2 as maximum dilution: freeze in growth medium plus 10% DMSO, low viability on resuscitation. Use of human serum produces high levels of debris in cultures.

Autres remarques

Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.